CSI Cancer at USC is led by Dr. Peter Kuhn (email: firstname.lastname@example.org) and each project is led by a team of patients, medical doctors, scientists and students focused on solving the clinical challenge through basic science breakthroughs that can be translated into real world solutions.
What We Do: Improve patient outcomes through science that describes the spatial and temporal evolution of the disease in each patient. Leverage single cell genomics and single cell proteomics (aka ‘no cell left behind’). Connect clinical and research data through mathematical models.
The Analytical Tools to Objectively Measure Human Performance (ATOM-HP) study has enrolled its first cancer patients!
This study aims to quantify Performance Status in cancer patients to complement the current clinical assessment. Data streaming from common sensors together with Patient Reported Outcomes with appropriate mathematical modeling will be able to accurately describe performance status from cancer patients, including any problematic changes that doctors need to address.
Performance Status (PS) of a patient is a clinical assessment that is key to understanding the patient’s fitness for the next treatment and is a critical determinant of how a patient responds to treatment. However, current PS evaluation is subjective, and patient-physician disagreement is associated...
Health Datapalooza, the meeting that brings data to life in ways that matter in health and health care, was held this week in Washington, DC.
Given the rapid pace of emerging advanced technologies and associated explosion of data generation, current computational models and visualization approaches are quickly becoming obsolete. A panel discussion at the conference explored the kinds of collaboration we must strive for to meet the goals of the Precision Medicine Initiative and the National Cancer Moonshot Initiative. The panelists described inter-agency projects and themes that can break down silos and bring us closer to a national learning healthcare system.
The Kuhn-Hicks Lab is proud to participate in innovative inter-agency pilots that support the next generation of care – new tools, models and approaches in cancer to provide a shift from observe and treat, to predict and prevent:
- Big Data Scientist Training Enhancement Program (BD-STEP)
- Analytic Tool for the Objective Monitoring of Human Performance (ATOM-HP)
- High Definition Single Cell Analysis of Blood and Tissue Biopsies in Patients with Colorectal Cancer Undergoing Hepatic Metastasectomy (HD-SCA in CRC)
FNIH announced today that Peter Kuhn will lead the project team for “High Definition Single Cell Analysis of Blood and Tissue Biopsies in Patients with Colorectal Cancer Undergoing Hepatic Metastasectomy” (HD-SCA in CRC).
The team is comprised of experts from the National Cancer Institute, the U.S. Food and Drug Administration, University of Southern California, Scripps Clinic, Baylor College of Medicine, Mayo Clinic and four sponsoring pharmaceutical companies.
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium is launching a research partnership to determine whether liquid biopsies can be used instead of traditional solid tumor biopsies for diagnosing and monitoring metastatic colorectal cancer. According to the American Can...
Congratulations to Dr. Jerry Lee on his new appointment to the White House Cancer Moonshot Task Force.
The Moonshot initiative, announced earlier this year by US President Barack Obama, aims to accelerate cancer research, patient treatment and care. Headed up by Vice President Joe Biden, the Task Force will focus on making the most of federal investments, cancer research and patient engagement initiatives. Dr. Lee will serve as Deputy Director for Cancer Research and Technologies.